Bloocell is a pioneering Turkish biotechnology company specializing in advanced 3D bioprinted tissue scaffolds for regenerative medicine. Founded in 2020, we have developed a proprietary 3D Bioprinting technology platform that creates biomimetic scaffolds with nano-to-micron scale precision, enabling true tissue regeneration across multiple clinical applications.
Core Technology & Expertise
Our manufacturing platform produces highly controlled fibrous architectures that replicate native tissue extracellular matrix (ECM) with unprecedented precision. Beyond structural mimicry, we integrate multi-functional surface modification strategies including:
Bioactive coatings for enhanced cell adhesion, proliferation, and differentiation
Controlled drug delivery systems for localized therapeutic release (antibiotics, growth factors, anti-inflammatory agents)
Anti-fouling and antimicrobial functionalization for infection prevention
Patient-specific customization through computational design and additive manufacturing
Clinical & Commercial Validation
Bloocell holds Turkey's first and only clinical approval for 3D bioprinted tissue scaffolds. Our bone and dental regeneration products (BCRM) are currently in active clinical use, demonstrating 2-3x faster healing compared to conventional treatments with over 4000+ patients. This clinical track record positions us uniquely among domestic medical device companies in the regenerative medicine sector.
To develop drug-eluting 3D printed scaffolds for tissue regeneration. Clinically approved platform ready for functionalization.
Consortium/Coordinator seeks Partners
Partner seeks Consortium/Coordinator
DESTINATION 3: HORIZON-HLTH-2026-01-DISEASE-15: Scaling up innovation in cardiovascular health
DESTINATION 6: HORIZON-HLTH-2026-01-IND-03: Regulatory science to support translational development of patient-centred health technologies
DESTINATION 5: HORIZON-HLTH-2026-01-TOOL-03: Integrating New Approach Methodologies (NAMs) to advance biomedical research and regulatory testing
DESTINATION 5: HORIZON-HLTH-2026-01-TOOL-05: Pilot actions for follow-on funding: Leveraging EU-funded collaborative research in regenerative medicine
DESTINATION 5: HORIZON-HLTH-2026-01-TOOL-07: Establishing a European network of Centres of Excellence (CoEs) for Advanced Therapies Medicinal Products (ATMPs)
DESTINATION 5: HORIZON-HLTH-2026-01-TOOL-06: Support to European Research Area (ERA) action on accelerating New Approach Methodologies (NAMs) to advance biomedical research and testing of medicinal products and medical devices